Compare TIMB & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | LNTH |
|---|---|---|
| Founded | 1998 | 1956 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 4.4B |
| IPO Year | 1998 | 2015 |
| Metric | TIMB | LNTH |
|---|---|---|
| Price | $21.70 | $66.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $22.75 | ★ $77.33 |
| AVG Volume (30 Days) | 324.9K | ★ 1.0M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | ★ 26.01 | N/A |
| EPS | 0.31 | ★ 2.39 |
| Revenue | ★ $4,941,546,695.00 | $1,525,933,000.00 |
| Revenue This Year | $8.02 | $0.01 |
| Revenue Next Year | $5.11 | $1.24 |
| P/E Ratio | ★ $13.75 | $27.84 |
| Revenue Growth | ★ 4.96 | 1.95 |
| 52 Week Low | $11.32 | $47.25 |
| 52 Week High | $23.88 | $111.29 |
| Indicator | TIMB | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 71.07 |
| Support Level | $21.44 | $60.15 |
| Resistance Level | $22.17 | $64.40 |
| Average True Range (ATR) | 0.46 | 2.02 |
| MACD | -0.13 | 0.72 |
| Stochastic Oscillator | 21.44 | 89.69 |
TIM, which is 67%-owned by Telecom Italia, is the third largest wireless carrier in Brazil, with 62 million subscribers, equal to about 24% of the market. The firm also owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 9 million locations, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand. TIM also resells fiber network access from other providers, including Oi's former infrastructure business V.tal.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.